RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has received a consensus rating of “Hold” from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $5.29.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of RAPT Therapeutics in a report on Monday, March 10th.

RAPT Therapeutics Stock Up 5.5 %

NASDAQ RAPT opened at $1.15 on Thursday. RAPT Therapeutics has a 52 week low of $0.79 and a 52 week high of $9.65. The business’s fifty day simple moving average is $1.17 and its 200-day simple moving average is $1.49. The firm has a market cap of $151.81 million, a PE ratio of -0.42 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.69). Research analysts expect that RAPT Therapeutics will post -2.14 EPS for the current year.

Institutional Trading of RAPT Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Readystate Asset Management LP acquired a new position in RAPT Therapeutics in the 3rd quarter valued at about $36,000. Barclays PLC grew its position in RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after acquiring an additional 29,195 shares in the last quarter. JPMorgan Chase & Co. grew its position in RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after acquiring an additional 25,130 shares in the last quarter. SG Americas Securities LLC grew its position in RAPT Therapeutics by 401.9% in the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after acquiring an additional 42,636 shares in the last quarter. Finally, Medicxi Ventures Management Jersey Ltd acquired a new position in RAPT Therapeutics in the 4th quarter valued at about $35,316,000. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.